



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

AF

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/712,447	11/13/2003	Gattadahalli M. Anantharamiah	112739.123US and NDA-122U	8707
7590	10/14/2005		EXAMINER	KOLKER, DANIEL E
THE UAB RESEARCH FOUNDATION AB 1120G ADMINISTRATION BLDG. 1530 3RD AVENUE SOUTH BIRMINGHAM, AL 35294-0111			ART UNIT	PAPER NUMBER
			1649	

DATE MAILED: 10/14/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/712,447	ANANTHARAMIAH ET AL.	
	Examiner	Art Unit	
	Daniel Kolker	1649	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 14 May 2004.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-34 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) _____ is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) 1-34 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
 Paper No(s)/Mail Date _____.
 4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date. _____.
 5) Notice of Informal Patent Application (PTO-152)
 6) Other: _____.

DETAILED ACTION***Election/Restrictions***

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1 – 8 and 14 - 17, drawn to peptides and compositions, classified in class 530, subclass 300.
 - II. Claims 10 – 13 and 26 - 27, drawn to nucleic acids, vectors, and host cells, classified in class 536, subclass 23.1, for example.
 - III. Claim 18, drawn to a monoclonal antibody, classified in class 530, subclass 388.1, for example.
 - IV. Claims 19 – 25 and 31 – 34, drawn to methods comprising contacting a polypeptide with a cell or administering a polypeptide to a subject, classified in class 514, subclass 14, for example.
 - V. Claims 28 – 30, drawn to transgenic non-human subjects, classified in class 800, subclass 13, for example.
2. Inventions I, II, and III are independent and distinct, each from each other, because they are products which possess characteristic differences in structure and function and each has an independent utility that is distinct for each invention which cannot be exchanged.

The polynucleotide of Group II and the polypeptide of Group I are patentably distinct for the following reasons: polypeptides, which are composed of amino acids, and polynucleotides, which are composed of purine and pyrimidine units, are structurally distinct molecules; any relationship between a polypeptide and polynucleotide is dependent upon the information provided by the nucleic acid sequence open reading frame as it corresponds to the primary amino acid sequence of the encoded polypeptide. Furthermore, searching the inventions of Groups I and II together would impose a serious search burden. In the instant case, the search of the polypeptides and the polynucleotides is not coextensive. The inventions of Groups I and II have a separate status in the art as shown by their different classifications. In cases such as this one where descriptive sequence information is provided, the sequences are searched in appropriate databases. There is also search burden in the non-patent literature. Prior to the concomitant isolation and expression of the sequence of interest there may be journal articles devoted solely to polypeptides which would not have described the polynucleotide. Similarly, there may have been "classical" genetics papers which had no

knowledge of the polypeptide, but spoke to the gene. Searching, therefore, is not coextensive. Furthermore, a search of the nucleic acid molecules of Group II would require an oligonucleotide search, which is not likely to result in relevant art with respect to the polypeptide of Group I. As such, it would be burdensome to search the inventions of Groups I and II.

The polypeptide of Group I and the antibody of Group III are patentably distinct for the following reasons: while the inventions of both Groups I and III are polypeptides, in this instance, the polypeptide of Group I is a single chain molecule, whereas the polypeptide of Group III encompasses antibodies including IgG which comprises 2 heavy and 2 light chains containing constant and variable regions, including framework regions which act as a scaffold for the 6 complementary determining regions (CDRs) that function to bind an epitope. Thus, the polypeptide of Group I and the antibody of Group III are structurally distinct molecules; any relationship between a polypeptide of Group I and an antibody of Group III is dependent upon the correlation between the scope of the polypeptides that the antibody binds and the scope of the antibodies that would be generated upon immunization with a polypeptide.

In this case, the polypeptide of Group I is a large molecule which contains potentially hundreds of regions to which an antibody must bind, whereas the antibody of Group III is defined in terms of its binding specificity to a small structure within the disclosed sequences. Thus, immunization with the polypeptide of Group I would result in the production of antibodies outside the scope of Group III. Therefore, the polypeptide and antibody are patentably distinct.

Furthermore, searching the inventions of Group I and Group III would impose a serious search burden. The inventions have a separate status in the art as shown by their different classifications. A polypeptide and antibody to which the polypeptide binds require different searches. An amino acid search of the full-length protein is necessary for a determination of novelty and unobviousness of the protein. However, such a search is not required to identify the antibodies of Group III. Furthermore, antibodies which bind to an epitope of a polypeptide of Group I may be known even if a polypeptide of Group I is novel. In addition, the technical literature search for the polypeptide of Group I and the antibody of Group III is not coextensive, e.g. antibodies may be characterized in the technical literature prior to discovery of, or sequencing of, their binding target.

The polynucleotide of Group II and the antibody of Group III are patentably distinct for the following reasons: the antibody of Group III includes, for example, IgG which comprises 2 heavy and 2 light chains containing constant and variable regions, including framework regions

Art Unit: 1649

which act as a scaffold for the 6 complementary determining regions (CDRs). Polypeptides, such as the antibody of Group III which are composed of amino acids, and polynucleotides, which are composed of nucleic acids, are structurally distinct molecules. Any relationship between a polynucleotide and polypeptide is dependent upon the information provided by the nucleic acid sequence open reading frame as it corresponds to the primary amino acid sequence of the encoded polypeptide. In the present claims, a polynucleotide of Group II will not encode an antibody of Group III, and an antibody of Group III cannot be encoded by a polynucleotide of Group II. Therefore, the antibody and polynucleotide are patentably distinct.

The antibody and polynucleotide inventions have a separate status in the art as shown by their different classifications. Furthermore, searching the inventions of Groups II and III would impose a serious search burden since a search of the polynucleotide of Group II would not be used to determine the patentability of an antibody of Group III and vice-versa.

Inventions I and IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the polypeptides of Group I can be used to make antibodies. Furthermore search for Group IV requires determining whether the products had been administered as claimed, which is not required for the search for Group I. Since the searches are not coextensive, there would be a serious burden for the examiner if the two groups were to be examined together.

Inventions I and III are not related to Invention V. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to patentably distinct products. The polypeptides and antibodies of groups I and III can be used on their own, neither is required for, nor can be used for, making a transgenic animal of group V. Consideration of group V requires search for animals, which is not required for either group I or III. Thus consideration of either group I or III with Group V would be burdensome for the examiner.

Inventions II, III, and V are not related to Invention IV. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the

Art Unit: 1649

instant case the different inventions cannot be used together. Group IV requires administration of a polypeptide, but none of groups II, III, or V are polypeptides. Since the methods of group IV cannot be performed with any of the products of groups II, III, or V, searches for the two sets of groups are not coextensive so consideration of any of groups II, III or V along with group IV would be burdensome.

Inventions II and V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to different products. While the nucleic acid of invention II can be used to generate a transgenic animal, it can also be used for many other processes, including in hybridization assays and in generation of protein. Search for the nucleic acid would not be informative as to the novelty of the transgenic animals, so consideration of groups II and V together would be burdensome.

3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter and because they require divergent searches, restriction for examination purposes as indicated is proper.

Requirement for Further Restriction Within All Groups

4. All pending claims are drawn to proteins recited in claim 1, or nucleic acids which encode same, or antibodies which bind to same, or transgenic animals comprising same. However claim 1 recites multiple protein sequences, each of which is patentably distinct. Each sequence has unique chemical and physical properties, and search for any one will not be informative as to the novelty of any other. In response to this office action, applicant must elect a single one of the following sequences for prosecution on the merits.

- a) SEQ ID NO:208
- b) the reverse of SEQ ID NO:208
- c) SEQ ID NO:209
- d) the reverse of SEQ ID NO:209
- e) SEQ ID NO:210
- f) the reverse of SEQ ID NO:210

Art Unit: 1649

Applicant is reminded of the rules for amino acid and nucleic acid sequences in patent applications, and that amendment may be required in order to comply with the rules if b), d), or f) is elected. See MPEP § 2420.

Applicant is advised that this is not a species election but is an additional requirement for restriction within the elected group.

Requirements for Elections of Species

5. This application contains claims directed to the following patentably distinct species of the claimed invention:

Polypeptide sequences:

Claims 4 and 5 are drawn to multiple specific polypeptide sequences, SEQ ID NO:1 – 207. Applicant must elect a single polypeptide sequence for prosecution on the merits. This requirement for election of species applies to all groups.

Animal Species

Claims 32 – 34 recite multiple species to which compounds are to be administered. If applicant elects Group IV for prosecution on the merits, applicant must elect a single one of the following species:

- a) human
- b) mouse
- c) rat
- d) rabbit
- e) cow
- f) sheep
- g) pig
- h) monkey
- i) ape
- j) chimpanzee
- k) orangutan

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held

Art Unit: 1649

to be allowable. Currently, claims 1 – 3 and 6 – 9 are generic with respect to polypeptides, and claims 19 – 25 are generic with respect to species.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

7. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.**

Art Unit: 1649

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Daniel Kolker whose telephone number is (571) 272-3181. The examiner can normally be reached on Mon - Fri 8:30AM - 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres can be reached on (571) 272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Daniel E. Kolker, Ph.D.

September 30, 2005

SHARON TURNER, PH.D.
PRIMARY EXAMINER

10-5-05